| Item
(pg/ml) |
Control
n = 20 |
Methotrexate
n = 63 |
Leflunomide
n = 31 |
IL-1-ser |
1,65 ± 0,03 |
BT 0,69 ±0,16*
AT 1,77 ± 0,73 |
BT 1,40 ± 0,14
AT 1,03 ± 0,13 |
IL-6-ser |
2,47 ± 0,03 |
BT 80,59 ± 35,17
AT 53,96 ± 27,17 |
BT 56,60 ± 12,54*
AT 31,11 ± 3,66* |
IL-10-ser |
0,21 ± 0,02 |
BT 0,25 ± 0,17
AT 0,31 ± 0,24 |
BT 4,81 ± 0,13*
AT 1,10 ± 0,02*◊ |
TNF-ser |
2,17 ± 0,07 |
BT 3,40 ± 1,47
AT 31,94 ± 8,37*◊ |
BT 5,34 ± 1,12
AT 6,42 ± 1,54 |
IL-1-sin |
1,95 ± 0,91 |
BT 11,12 ± 3,36
AT 0,65 ± 0,12 ◊ |
BT 12,55 ± 2,87*
AT 4,77 ± 1,38 ◊ |
IL-6-sin |
3,48 ± 1,12 |
BT 1446,76±124,84*
AT 1820,34 ±23,65* |
BT 1670,54 ± 89,44*
AT 1856,49 ± 76,88* |
IL-10-sin |
1,11 ± 1,02 |
BT 7,68 ± 1,43
AT 43,80 ± 2,62*◊ |
BT 14,87 ± 1,55*
AT 64,33 ± 1,81*◊ |
TNF-sin |
4,12 ± 2,03 |
BT 164,51 ± 18,45*
AT 25,50 ± 3,76*◊ |
BT 170,45 ± 12,77*
AT 22,87 ± 2,02*◊ |
Note: n — number of patients in each group. * — differences from the control were significant at р<0.05. ◊ — differences between the groups were significant at р<0.05.
BT – before treatment. AT – after treatment |
